Hematologic Oncology | Specialty

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

September 26th 2018

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Dr. Yang on the Future of Acute Myeloid Leukemia

September 26th 2018

Jay Yang, MD, oncologist, Barbara Ann Karmanos Cancer Institute, discusses the future of acute myeloid leukemia (AML).

Expert Recaps Advances in AML

September 26th 2018

Rami S. Komrokji, MD, reflects on the diverse acute myeloid leukemia treatment landscape and touches on the prognostic importance of biomarkers.

Dr. Zonder on Induction Therapy in Newly Diagnosed Multiple Myeloma

September 26th 2018

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.

Dr. Uberti on Transplant in Myelodysplastic Syndrome

September 26th 2018

Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).

Dr. Kreitman on the Prognosis of Hairy Cell Leukemia

September 25th 2018

Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the prognosis for patients diagnosed with hairy cell leukemia.

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

FDA Lifts Partial Clinical Hold on Tazemetostat Trials

September 24th 2018

The FDA has lifted a partial clinical hold on tazemetostat trials, reopening enrollment to clinical studies examining the EZH2 inhibitor in patients with various solid tumors and hematologic malignancies.

Recent Data Support TKI Discontinuation in Patients With CML

September 24th 2018

Kendra Sweet, MD, sheds light on data regarding treatment discontinuation and how they impact patients with chronic myeloid leukemia.

Dr. Cohen on the Evolution of Antibodies in Lymphoma

September 22nd 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.

Future Treatment Approaches to AML

September 20th 2018

Moving the AML Treatment Landscape Forward

September 20th 2018

Optimizing the Use of FLT3 Inhibitor Therapy for AML

September 20th 2018

Long-Term Challenges With FLT3 Inhibition in AML

September 20th 2018

Testing for FLT3 Mutations in the Community Setting of AML

September 20th 2018

Quizartinib's Potential Role in Treating AML

September 20th 2018

Personal Experience Managing AML With Quizartinib

September 20th 2018

Evaluating Data From QuANTUM-R: Quizartinib in AML

September 20th 2018

Utilizing FLT3 Inhibitors in Relapsed/Refractory AML

September 20th 2018

Evaluating Single-Agent Use of FLT3 Inhibition in AML

September 20th 2018